Q-omics provides the consensus-scored LYSMD4 profile across patient tissues and cancer cell-line models. LYSMD4 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, LYSMD4 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, LYSMD4 RNA expression shows 20,914 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where LYSMD4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LYSMD4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LYSMD4 survival associations across molecular data types. LYSMD4 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LYSMD4 RNA expression–survival associations across cancer types. High LYSMD4 expression shows unfavorable associations in ACC, LIHC and LGG, but favorable associations in UCS, KIRC and OV. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for LYSMD4 RNA expression.
This table summarizes LYSMD4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for LYSMD4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LYSMD4 shows lower tumor expression in KICH, LUAD, BRCA and KIRP and higher tumor expression in HNSC and LIHC. The HNSC box plot shows higher LYSMD4 RNA expression in tumor versus normal tissue (log2 FC = +0.580, t-test p < 0.001).
This table shows molecular features associated with LYSMD4 in patient tissues and cancer cell lines. In patient samples, LYSMD4 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, LYSMD4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LARGE_INTESTINE.
